Overall rank by patents
#36,444
of 49,997 tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).
The verdict
According to USPTO PatentsView, Medtrace ranks #36,444 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R36444 · Foreign Corporation #36,444 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: McNaughton Incorporated (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
MedTrace Pharma A/S · this assignee
42 score
3D Lighting… · lowest
7 score
What this shows Medtrace's Innovation Score is 42.3/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
MedTrace Pharma A/S is a focused PatentsView assignee: 6 CPC subclasses with 85.7% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). By volume, Medtrace sits between McNaughton Incorporated and MediPines Corporation.
MedTrace Pharma A/S shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
McNaughton Incorporated
7 patents
Med-Life Discoveries LP
7 patents
MedInTech Inc.
7 patents
MedRhythms, Inc.
7 patents
Medcomb Holding APS
7 patents
Mederi RF, LLC
7 patents
Medgenics Medical Israel Ltd.
7 patents
MediPines Corporation
7 patents
MedTrace Pharma A/S
7 patents
What this shows MedTrace holds 7 patents at rank #36,483, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #36,483 in granted patent volume.
Other assignees with the most granted patents in MedTrace's primary technology class.
Medtrace's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
42 Top 31% higher than 69% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
| 2023 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
| 2025partial year | 3 | 42.9% |
Top 6 of 6 technology areas
Overall rank by patents
#36,444
of 49,997 tracked assignees
42.3 out of 100
What to do with this data
MedTrace Pharma A/S's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.